Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

Conference item

The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.

Authors: Jaoko, W; Nakwagala, F; Anzala, O; Manyonyi, G; Birungi, J

• Publication status: Published
• Host title: Vaccine
• Volume: 26
• Issue: 22
• Pages: 2788-2795
• Publication date: 2008-05-01
• Event location: Netherlands
• DOI: 10.1016/j.vaccine.2008.02.071
• EISSN: 1873-2518
• ISSN: 0264-410X
• Keywords: Vaccinia virus; Flow Cytometry; Vaccines, DNA; Humans; Interferon-gamma; Adult; Kenya; Leukocytes, Mononuclear; Female; Uganda; Epitopes, T-Lymphocyte; HIV-1; AIDS Vaccines; gag Gene Products, Human Immunodeficiency Virus; Placebos; Plasmids; Genetic Vectors; Male